@article{oai:redcross.repo.nii.ac.jp:00012214,
 author = {西脇, 崇裕貴 and 竹中, 勝信 and 加藤, 雅康 and 野中, 裕康 and 趙, 振新 and 岡本, 清尚},
 journal = {高山赤十字病院紀要, Japanese Red Cross Takayama Hospital},
 month = {Mar},
 note = {A lot of studies of O6-methyguanine DNA methyltransferase (MGMT) protein expression have
been reported in glioma. However, there are few reports assessed the protein expression in other
brain tumors except glioma.
METHODS: Five brain tumors except glioma (two primary central nervous system lymphomas;
PCNSLs, one germinoma, one hemangioblastoma, and one Rathke’s cleft cyst) were immunostained
using a commercial anti-MGMT antibody (Chemicon international:MAB16200;clone MT3.1). Three
glioblastomas were also immunostained with the same antibody. We assessed MGMT protein
expression semiquantitatively (low expression was defined as 20～50% immunostained tumor cells,
and high expression was defined as ＞50% immunostained tumor cells ).
RESULTS: Two PCNSLs were assessed as high expression. Germinoma was also assessed as high
expression. In contrast, Hemangioblastoma was assessed as low expression and Rathke’s cleft
cyst was no expression.
CONCLUSIONS: By using immunohistochemical assessment of MGMT protein expression, it might
help us to understand the features in brain tumors except glioma.},
 pages = {43--45},
 title = {悪性神経膠芽腫（グリオーマ）以外の脳腫瘍における O6-methylguanine-DNA methyltransferase （MGMT）抗体の染色性の検討},
 volume = {40},
 year = {2017}
}